- Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations
- The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://cnw.fm/SOjPD).
During the animal study, it was determined that in as little as four minutes after dosing, the DehydraTECH formulation of sildenafil delivered 74% more of the PDE5 inhibitor into the bloodstream on average than the concentration-matched, generic control formulation. Within seven minutes, the DehydraTECH-sildenafil formulation achieved a higher average blood level than the generic control reached at any point during the study.
The most well-known sildenafil product on the market is Viagra(R). The medication is bioavailable orally at approximately 40%, with the most common complaint by consumers that it is slow to act. The findings of Lexaria’s animal study are a first step to developing faster and better acting sildenafil oral formulations.
In addition to this successful study, as well as a pivotal human clinical trial investigating DehydraTECH-processed cannabidiol (“CBD”), the company announced plans for more trials this year, as per its annual letter to shareholders outlining milestones in 2021 and plans and expectations for 2022. “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018! We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” CEO Chris Bunka stated in the letter (https://cnw.fm/YZNMd).
Lexaria’s most significant area of investigation for 2022 is DehydraTECH-processed-CBD for potential hypertension and heart disease treatment and
Bunka explained that starting in April (or sooner), the company will begin the largest-ever hypertension study. “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022.”
With all these achievements and plans for further development, the company is positioned to secure an important role in the global drug delivery devices market, an expanding sector expected to reach $31.67 billion by 2027 from an estimated $23.1 billion in 2021 (https://cnw.fm/6kAe5). Key factors driving this growth are the rising geriatric population, coupled with the rise of non-communicable diseases (diabetes, cancer, etc.). This surge has also led to a higher demand for non-invasive drug delivery methods.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.canadiancannabiswire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.